Government watchdog attacks FDA conflicts plan

The FDA's plan to reconsider conflict-of-interest rules governing its advisory-panel experts is drawing fire from the Project on Government Oversight, which argues that the regulations should not be loosened. Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…